These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30041014)

  • 1. Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway.
    Salminen WF; Wiles ME; Stevens RE
    Drug Discov Today; 2019 Jan; 24(1):46-56. PubMed ID: 30041014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US FDA 505(b)(2) NDA clinical, CMC and regulatory strategy concepts to expedite drug development.
    Salminen WF; Aloba O; Drew A; Marcinowicz A; Huang M
    Drug Discov Today; 2023 Jul; 28(7):103618. PubMed ID: 37196760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
    Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
    Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements.
    Freije I; Lamouche S; Tanguay M
    Ther Innov Regul Sci; 2020 Jan; 54(1):128-138. PubMed ID: 32008242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
    Rising K; Bacchetti P; Bero L
    PLoS Med; 2008 Nov; 5(11):e217; discussion e217. PubMed ID: 19067477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of US Food and Drug Administration review intervals for drugs approved during the period 1997-2002.
    Kros JF; Qian J
    Am J Ther; 2004; 11(5):337-43. PubMed ID: 15356429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin products for oral use; revocation of conditions for marketing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(123):42992-7. PubMed ID: 12120661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
    Knoben JE; Scott GR; Tonelli RJ
    Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
    Barrio JR; Marcus CS; Hung JC; Keppler JS
    Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs).
    Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
    AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.